Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients

Skin and Connective Tissue Diseases Clinical Trial

— MFC  

Official title:

Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients as Compared to Controls

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05525741
• Other study ID #: 22-PP-10
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 19, 2022
• Est. completion date: August 30, 2024

Study information

• Verified date: March 2024
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare the level of circulating functional mitochondria in the serum of vitiligo patients as compared to controls

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 59
• Est. completion date: August 30, 2024
• Est. primary completion date: April 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with non segmental vitiligo,

• atopic dermatitis, psoriais, alopecia areata,

• 1st degree relative of vitiligo patients.

Exclusion Criteria:

• segmental or mixed vitiligo,

• personnal history of other autoimmune disorders,

• oral use of antioxidant,

• pregant women

Related Conditions & MeSH terms

• Connective Tissue Diseases
• Skin and Connective Tissue Diseases
• Vitiligo

Intervention

Other:
• Non segmental vitiligo
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: Inform the subject of the goals, constraints and risks of the study and obtain written consent. Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
• Health Volunteers
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: Inform the subject of the goals, constraints and risks of the study and obtain written consent. Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Locations

Country	Name	City	State
France	CHU de Nice - Hôpital de l'Archet	Nice	Alpes-maritimes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total number of circulating functionnal mitochondria (CFM) in the plasma	Level of CFM in vitiligo serum as compared to controls	at baseline
Secondary	measuring the functionality of circulating mitochondria	Functional analysis of CFM in vitiligo patients as compared to controls analyzed by MFI Mito Tracker	At baseline